Sonikure Technology is founded in 2014 by three HKUST Postgraduate students with different academic backgrounds. Sonikure participated in several national and international business plan competitions and is awarded second place of the HKUST 1 Million Dollar Entrepreneurship competition 2014, winner of the TiE Hong Kong chapter entrepreneurship competition 2015, winner of the TiE Regional Asia competition in Delhi India 2015, top 8 teams in the Rice business plan competition 2015, one of the largest and richest graduate students competitions in the world. The company also received several funding supports from HKUST and the HK government for developing a prototype and carrying out clinical studies.
Having a total global ophthalmic drug market worth USD 20 billion in 2015, the retinal disease market takes the largest share with USD6.7bn with an annual growth rate of > 14% until 2020. Patients in developed countries most commonly retreaving invasive needle injections, whereby a huge part (47%) doesn’t get injections at all. These 47% of the total patient number is a huge untapped market which can be more easily entered through the new non-invasive treatment method. Further it’s a win-win situation as more patients can get retinal treatments but also hospitals, clinics and eye doctors can increase their patient number.
Invention - Ultrasound Enhanced Delivery of Drug into the Eye via Transscleral Route
Retinal diseases are commonly treated with invasive needle injection, resulting in several follow up side effect like retinal bleeding, increased eye pressure or also inflammation. The project “Ultrasound enhanced delivery of drug into the eye via transscleral route” focus on the delivery of different type of high molecular weight drugs, which are commonly used for treating retinal diseases. The delivery mechanism is based on completely non-invasive ultrasound technique, using low frequency low-intensity ultrasound which showed no side effects in animals testing.
Highlight of the Technology
2. Low risk of side effects
3. Compatible with commercial available eye drugs
4. High drug delivery efficiency
5. Easy to use
2/F Kam Chung Commercial Building, 19-21 Hennessy Road, Wan Chai, Hong Kong